Trusts can take cost into account when deciding drug treatment

BMJ 2006; 332 doi: 10.1136/bmj.332.7547.928-a (Published 20 April 2006)
Cite this as: BMJ 2006;332:928.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Clare Dyer, legal correspondent
  1. BMJ

    Last week's Appeal Court judgment to force the NHS to pay for trastuzumab (Herceptin) will not oblige primary care trusts to fund the drug for every woman whose oncologist prescribes it—although most of the media reported that it would.

    Three Appeal Court judges headed by the master of the rolls, Anthony Clarke, unanimously ruled that Swindon NHS Primary Care Trust irrationally and unlawfully refused to pay for the treatment for Ann Marie Rogers, 54, who has early stage HER2 positive breast cancer.

    The drug has been licensed and assessed …

    Access to the full text of this article requires a subscription or payment

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL